CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

203565Orig1s000

CROSS DISCIPLINE TEAM LEADER REVIEW

Cross-Discipline Team Leader Review

Date	July 23, 2013
From	Kathy M. Robie Suh, M.D., Ph.D.
Subject	Cross-Discipline Team Leader Review
NDA	203565
Applicant	Luitpold Pharmaceuticals, Inc.
Date of Submission	January 30, 2013; received January 30, 2013
PDUFA Goal Date	July 30, 2013
Proprietary Name / Established (USAN) names	Injectafer (ferric carboxymaltose)
Dosage forms / Strength	Injection (single-use vials (b) (4) 750 mg iron/15 mL
Proposed Indication(s)	for the treatment of iron deficiency anemia
Recommended:	Approval

1. Introduction

Injectafer (ferric carboxymaltose; FCM) is an iron formulation developed for parenteral administration for the treatment of iron deficiency anemia. The sponsor's proposed indication is:

"Injectafer is indicated for the treatment of iron deficiency anemia:

- (b) (4) (b) (4) are intolerant to oral iron (b) (4) have had unsatisfactory response to oral iron.
- (b) (4) chronic kidney disease"

The proposed dosing is 15 mg/kg up to a maximum single dose of 750 mg of iron on two occasions separated by at least 7 days up to a cumulative dose of 1500 mg of iron delivered by intravenous infusion or injection.

Ferric carboxymaltose (marketed as Ferinject[R]) is approved in the European Union (2007) and in over 40 countries worldwide.

The current submission is a resubmission in response to a Complete Response (CR) letter issued for this 505(b)(1) application on July 23, 2012. The application was not able to be approved at that time due to Chemistry, Manufacturing and Controls (CMC) deficiency for the drug product manufacture leading to an overall withhold recommendation for the inspections of the manufacturing and testing facilities. The CR letter also included Agency recommendations for labeling and the current submission includes the sponsor's draft labeling. Please refer to the previous CDTL Review (K Robie Suh, signed July 21, 2012) for summary of the findings of the first cycle application review.

2. CMC/Device

The chemistry, manufacturing and controls (CMC) information in this resubmission has been reviewed by WM Adams, Office of New Drug Quality Assessment (ONDQA) (review signed in DARRTS June 26, 2013). The review states:

> Complete and acceptable chemistry, manufacturing, and controls (CMC) information has been provided to support approval of this application, however an overall recommendation by the Office of Compliance (OC) for the GMP inspections of the proposed manufacturing and testing facilities for the drug substance and drug product is still *pending*. Therefore, the application cannot be approved.
>
> Based on the provided stability data, a 24-month expiration dating period is granted for the drug product when stored at the USP controlled room temperature.

Some recommendations are made for labeling revisions for Section 11, Section 16 and Footer and for the Patient Information leaflet.

Subsequent to the June 16, 2013 CMC review the final Office of Compliance (OC) recommendation for the NDA was entered in EES. The followup CMC Memorandum (WM Adams, 7/21/2013) states:

> NDA 203565 for Injectafer® (ferric carboxymaltose injection) re-submitted on 30 Jan 2013 with manufacture and control sites that differ from those listed in the initial NDA submission. CMC Review #3 (dated 25-Jun-2013) concluded that the application should not be approved in that an overall acceptable recommendation from the Office of Compliance and labeling issues were pending.
>
> The Office of Compliance issued an overall recommendation of Acceptable on 05-Jul-2013 and labeling meetings have been scheduled. Accordingly, from a CMC perspective, NDA 203565 is considered to be acceptable for approval.

3. Nonclinical Pharmacology/Toxicology

The non-clinical Pharmacology/Toxicology primary review of the resubmission was conducted by BJ Gehrke (final signature 6/25/2013). The review referenced the previous Pharmacology/Toxicology review (BJ Gehrke, 6/13/12) stating there were no pharmacology/toxicology concerns with the application and indicated that the resubmission does not contain any new pharmacology/toxicology information. The review concluded:

> **Recommendation:**
> Recommending approval. There are no pharmacology/toxicology issues for NDA 203565 to preclude approval of the drug for the proposed indication.

Comments and recommendations for labeling are included in the June 13, 2012 Pharmacology/Toxicology review.

4. Clinical Pharmacology/Biopharmaceutics

Please refer to the previous CDTL Review (K Robie Suh, signed July 21, 2012) for summary of the findings of the first cycle Clinical Pharmacology review of the application.

Note that the clinical pharmacology information for FCM was reviewed by J Christy (5/30/2007 under NDA 22054). That review concluded that the dose of FCM had not been optimized and recommended that the sponsor study doses lower than the 1000 mg dose being proposed in that NDA, because “a lower dose such as 500 mg and 800 mg may be equally efficacious clinically.”

There was no Clinical Pharmacology review for this review cycle. Clinical Pharmaocology participated in the labeling discussions.

5. Clinical Microbiology

Product Quality Microbiology Review by SP Donald (signed 4/30/2013) stated the following:

> C. **REMARKS:** An alternate manufacturing site, [redacted] (b) (4) is proposed. The applicant's letter of December 5, 2012 indicates a manufacturing site change. Section 3.2.P.3 in the subject submission lists only the [redacted] (b) (4) location as the manufacturing site for the subject drug product, but at the top of the page it states: "In addition to those facilities previously identified within this NDA, the following facilities may be used for the indicated services associated with the manufacture of Injectafer at the alternate [redacted] (b) (4) manufacturing facility". The subject submission provides only data for the 15 ml vial containing 750 mg iron. References to the [redacted] (b) (4) vial are stated to have been removed from the batch records and other configurations of the drug product are not mentioned. It appears that at this time, this alternate facility will manufacture only the 750 mg configuration and manufacturing at the previously reviewed facility will remain unchanged. The Product Quality Microbiology review, dated 5/08/2012, which covered manufacturing at the [redacted] (b) (4) facility, recommended the submission for approval. After the initial review of the 1/30/2013 submission, an information request was sent to the sponsor on 4/2/2013. A response dated 4/12/2013 was provided for review and is included herein.

The Microbiology review found the resubmission acceptable and recommended for approval. There were no recommendations for Phase 4 commitments.

6. Clinical/Statistical- Efficacy

The sponsor conducted two pivotal studies in support of this application, 1VIT09030 and 1VIT09031. Both were randomized, open-label, active controlled studies. The detailed Clinical Review of this application was conducted by M. Lu (signed 6/8/2012); secondary clinical review was conducted by KM Robie Suh (signed 7/20/2012); and Statistical Review was conducted by K-Y Lee (signed 6/28/2012). The review concluded that efficacy had been demonstrated. See those reviews for detailed discussion of efficacy findings.

See the previous CDTL review (KM Robie Suh, 7/21/2012) for summary of efficacy findings.

No efficacy data are included in the resubmission.

7. Safety

The detailed Clinical Review of this application was conducted by M. Lu (signed 6/8/2012); secondary clinical review was conducted by KM Robie Suh (signed 7/20/2012); and Statistical Review was conducted by K-Y Lee (signed 6/28/2012). See those reviews for detailed presentation of the clinical safety findings from the initial NDA submission. See the previous

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.